Want to see JP:5592 full AI Analyst Report?
Kusurinomadoguchi, Inc. (5592) AI Stock Analysis
Kusurinomadoguchi, Inc.
(TSE/TYO:5592)
The overall score of 83 reflects Kusurinomadoguchi's strong financial performance, bullish technical trend, and attractive valuation. The company's robust revenue growth, high profitability, and solid balance sheet are the primary drivers. While overbought technical indicators signal caution, the low P/E suggests the stock remains undervalued.
Kusurinomadoguchi, Inc. (5592) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 25.40B
- Dividend Yield
- 1.70%
- Average Volume (3M)
- 50.47K
- Price to Earnings (P/E)
- 7.9
- Beta (1Y)
- 0.83
- Revenue Growth
- 13.72%
- EPS Growth
- 43.20%
- Country
- Japan
- Employees
- 491
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Healthcare Information Services
Kusurinomadoguchi, Inc. Business Overview & Revenue Model
Company Description
Kusurinomadoguchi, Inc., established in 2004 and headquartered in Tokyo, Japan, develops and implements a diverse array of technology solutions specifically designed for pharmacies and the wider medical care sector throughout the country. Its compreh...
Kusurinomadoguchi, Inc. Financial Statement Overview
Summary
Kusurinomadoguchi demonstrates strong revenue growth (5-year CAGR ~14%), expanding margins (net margin 24% in 2026), and a robust balance sheet (debt-to-equity 0.25, ROE 26%). Cash flows are healthy despite a temporary dip in 2025. The composite score of 84 reflects solid financial health.
Income Statement
88Very PositiveBalance Sheet
85Very PositiveCash Flow
78Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.06B | 12.33B | 11.20B | 8.72B | 7.42B | 6.49B |
| Gross Profit | 7.38B | 6.97B | 6.48B | 4.93B | 4.07B | 3.37B |
| EBITDA | 4.38B | 4.19B | 2.97B | 2.35B | 1.68B | 1.51B |
| Net Income | 3.19B | 2.95B | 2.03B | 870.92M | 391.45M | 515.61M |
Balance Sheet | ||||||
| Total Assets | 18.23B | 17.82B | 12.16B | 23.07B | 12.22B | 11.02B |
| Cash, Cash Equivalents and Short-Term Investments | 4.51B | 5.20B | 2.15B | 14.59B | 5.95B | 5.02B |
| Total Debt | 2.88B | 2.82B | 72.47M | 5.42B | 137.49M | 149.56M |
| Total Liabilities | 6.77B | 6.35B | 3.64B | 16.65B | 9.43B | 8.06B |
| Stockholders Equity | 11.35B | 11.35B | 8.45B | 6.37B | 2.70B | 2.45B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 2.93B | -5.37B | 999.21M | 1.57B | 2.58B |
| Operating Cash Flow | 0 | 2.95B | -5.33B | 2.63B | 3.10B | 3.66B |
| Investing Cash Flow | 0 | -2.30B | -1.80B | -1.79B | -1.54B | -541.10M |
| Financing Cash Flow | 0 | 2.22B | -5.36B | 7.81B | -635.39M | -564.83M |
Kusurinomadoguchi, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:5592, the sentiment is Negative. The current price of 2230.00 is below the 20-day moving average (MA) of 2415.00, below the 50-day MA of 2566.04, and below the 200-day MA of 2588.28, indicating a bearish trend. The MACD of -89.34 indicates Positive momentum. The RSI at 29.12 is Positive, neither overbought nor oversold. The STOCH value of 13.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:5592.
Kusurinomadoguchi, Inc. Peers Comparison
Overall Rating
- JP:559283Outperform
JP:448372Outperform
JP:448063Neutral
JP:443850Neutral
JP:426339Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:5592 | 83Outperform | JPY 26.29B | 7.88 | ― | 1.70% | 13.72% | 43.20% |
| JP:4483 | 72Outperform | JPY 241.50B | 33.42 | ― | 0.51% | 18.89% | 11.66% |
| JP:4480 | 63Neutral | JPY 75.89B | 38.64 | 12.35% | ― | 24.03% | 34.50% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4438 | 50Neutral | JPY 2.36B | -4.51 | ― | ― | 14.84% | 30.67% |
| JP:4263 | 39Underperform | JPY 5.63B | -14.18 | ― | ― | 7.39% | -27.77% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:5592 | Kusurinomadoguchi, Inc. | 2230.00 | -791.63 | -26.20% | |
| JP:4480 | Medley, Inc. | 2323.00 | 191.00 | 8.96% | |
| JP:4263 | SUSMED,Inc. | 322.00 | -615.00 | -65.64% | |
| JP:4438 | Welby Inc. | 282.00 | -7.00 | -2.42% | |
| JP:4483 | JMDC Inc. | 3540.00 | -1326.33 | -27.26% |
Kusurinomadoguchi, Inc. Corporate Events
Kusurinomadoguchi Maps Out Q1 Results and Multi‑Year Healthcare Tech Strategy
Kusurinomadoguchi, Inc. reported its financial results for the first quarter of the fiscal year ending March 2027, outlining performance across its main healthcare technology segments. The briefing indicates that management is using this reporting pe...
Kusurinomadoguchi Delivers Strong Q1 as New Acquisitions Lift Earnings
Kusurinomadoguchi reported robust Q1 FY2027 consolidated results, with revenue rising 25.0% year on year to ¥3,643 million and net income attributable to owners of the parent surging 61.0% to ¥623 million. Earnings per share climbed to ...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026